Exchange: NASDAQ·Updated 10:54 AM EDT

AACPApogee Acquisition Corp. - Ordinary Shares - Class A

$9.96
$0.0025
(0.03%)
Today
Mkt Cap$179.86M
Vol16,100.00
News
all
press releases
News Placeholder
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.read more...
Benzinga
<
...
1
>
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.